Navigation Links
MDS Reports Second Quarter 2008 Results
Date:6/5/2008

Net Revenue up 24%, Adjusted EBITDA up 10%

TORONTO, June 5 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today reported its second quarter 2008 results for the period ended April 30, 2008. For the quarter, MDS reported total revenue of $350 million, net income of $11 million and earnings per share from continuing operations of $0.09. Net revenue was $326 million and adjusted EBITDA was $34 million, up from $263 million and $31 million in the prior year, respectively. Adjusted earnings per share were $0.06, down from $0.11 in the prior year.

Quarterly Highlights

- Delivered net revenue of $326 million, up 24% from $263 million in

the prior year. Excluding the impact of foreign exchange and

acquisitions, net revenue increased 5%.

- Increased adjusted EBITDA to $34 million, up 10% from $31 million in

the prior year.

- Reported adjusted earnings per share of $0.06, down from $0.11 in the

prior year, impacted by $0.04 of intangible asset amortization from

the Molecular Devices acquisition.

- MDS Pharma Services had another quarter of strong new business wins,

up 60% from prior year to $165 million. The business delivered

$128 million in net revenue and a loss of $1 million in adjusted

EBITDA compared to breakeven in the prior year.

- MDS Nordion delivered solid performance in Q2 reporting revenue of

$80 million, up 13% from $71 million in the prior year. Adjusted

EBITDA increased 9% to $24 million versus $22 million last year.

- MDS Analytical Technologies delivered $118 million in revenue

compared to $77 million in the prior year. Adjusted EBITDA increased

13% from $15 million to $17 million and was impacted by softening

demand for high-end instruments.

-
'/>"/>

SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. MedAmerica Reports Solid Growth, Outperforms Industry
2. Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008
3. Haemacure Reports on Financing Progress and Second Quarter Results
4. Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO
5. Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex
6. Chem Rx Corporation Reports First Quarter 2008 Financial Results
7. CRH Medical reports Q1 2008 results
8. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
9. Unilens Vision Reports Increased Royalty Income
10. China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008
11. Shamir Optical Industry Ltd. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... 22, 2015 State Forestry Institute of ... system with support from GEOSYSTEMS, a dedicated Hexagon Geospatial ... will leverage Hexagon Geospatial’s ERDAS APOLLO for ... well as point clouds and documents. This effort will ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... to normalize up, to 600,000 internally displaced residents of Baghdad into ... ... 6 Dr. Said Hakki, president,of the Iraqi Red Crescent Organization ... discuss the organization,s,Neighborhood Reconstruction Program (NRP) to immediately assist up to,600,000 ...
... Some of the UKs leading experts in location technologies ... hospitals are already improving the efficiency and quality of ... between hardware and software applications, and a lack of ... NHS is not benefiting as much as it could. ...
... GREAT RIVER, N.Y., May 6 VirtualCDO acted ... the sale of the company to Lawson,Software (St. ... management,software and services, assisted healthcare, hospitality and government,service ... enterprise,software and enterprise management services to some 4,000 ...
... Patients, Safety,Concerns, But Lack Confidence About Best Ways ... As patient safety,incidents in America,s hospitals continue ... hospital CEOs feel strongly confident about practices in,place ... the VHA Foundation,today formally launched the "Health Care ...
... Institute (HMRI) and Xstrata Coal will today announce a significant ... asthma in the Hunter and beyond. , Xstrata Coal has ... a newly recognised type of asthma which accounts for 50 ... Asthma Research Fellow, Dr Katie Baines from the University of ...
... experience can be deadly, say authors of a new survey ... often underestimate their level of driving experience, putting them at ... , And while many teens recognize that drinking and driving ... distraction posed by having friends in the car. , "We ...
Cached Medicine News:Health News:Dr. Said Hakki, President of Iraqi Red Crescent Organization, in the United States and Available for Interviews May 12-16 2Health News:Dr. Said Hakki, President of Iraqi Red Crescent Organization, in the United States and Available for Interviews May 12-16 3Health News:Location! Location! Location technologies are improving NHS care 2Health News:VirtualCDO Acts as M&A Advisor in Sale of VasTech to Lawson Software 2Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 2Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 3Health News:Many Teen Drivers Don't Think They're Inexperienced 2Health News:Many Teen Drivers Don't Think They're Inexperienced 3
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Shire plc (LSE: SHP,Nasdaq: SHPGY), the global ... scientific meeting findings from analyses of pivotal ... compound is an,investigational once-daily medication, which is ... of Attention Deficit Hyperactivity Disorder,(ADHD). The data ...
... and 2 Data Expected at ASCO in June ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... has completed patient enrollment in,its Phase 2 clinical ... of metastatic colorectal cancer (CRC). Early,data from this ...
Cached Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4
...
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Medicine Products: